Gene test could tailor chemo doses for rare cancer
NCT ID NCT06406465
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 34 times
Summary
This phase 2 trial is testing whether adjusting the dose of the drug belinostat based on a person's genetics can make treatment safer and more effective for high-grade neuroendocrine carcinoma. About 60 adults will receive belinostat along with two other chemotherapy drugs, cisplatin and etoposide. The goal is to see if genetic testing can help doctors give the right dose to each patient.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- belinostat, cisplatin, etoposide
- What this could lead to
- If successful, this could lead to personalized dosing of belinostat based on a person's genetics, making treatment safer and more effective for high-grade neuroendocrine cancer.
- What could go wrong
- This is a small, early-phase trial with only 60 participants. The genetic approach may not improve outcomes, and the drugs have significant side effects like low blood counts and organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NEUROENDOCRINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a black seed extract boost immunotherapy against a rare cancer?
- Can a radioactive drug shrink Slow-Growing tumours?
- New drug cocktail aims to fight rare cancer
- Double-Action antibody takes on Hard-to-Treat neuroendocrine cancers
- Two-Drug combo aims to stall rare gut tumors
- Could a PARP inhibitor boost chemo for tough lung cancer?